In conclusion, we demonstrate that although ID treatment using cisplatin, especially in combination with PARP-inhibition successfully attenuates tumor formation in a clinically relevant mouse model of BRCA1-associated breast cancer, it leads to long-term local and systemic secondary malignancies in mice and may not be safe in humans. This evidence concerns the gene PARP1 and breast cancer.